Skip to main content
STOK
NASDAQ Life Sciences

Stoke's Zorevunersen Shows Durable Seizure and Cognitive Gains in 4-Year Dravet Data

Tom Rudovsky · Reported by BusinessWire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$29.99
Mkt Cap
$1.935B
52W Low
$18.8
52W High
$40.22
52W Position info
60% above low
Off High info
25% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

STOK sits 60% above its 52-week low of $18.8.

Summary

Stoke and Biogen presented long-term data from Phase 1/2a and open-label extension studies of zorevunersen in Dravet syndrome at the European Epilepsy Congress. The 4-year results show 77% of patients remaining on treatment, with statistically significant improvements in cognition and behavior at every yearly timepoint. A new sub-analysis found substantial reductions in the most severe seizure types (GTC and focal-to-BTC), which are the leading risk factor for SUDEP. Quality of life also improved through 28 months. Safety remains generally well tolerated, though elevated CSF protein occurred in 94% of patients without serious clinical manifestations. These data strengthen the disease-modifying profile ahead of the Phase 3 EMPEROR readout expected in Q3 2027. The news is most material for Stoke, which retains U.S. rights; Biogen holds ex-U.S. commercialization rights.

At the time of this announcement, STOK was trading at $29.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $18.80 to $40.22. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.


Price Chart

Share this article

Copied!

STOK - Latest Insights

STOK
Nov 03, 2026, 4:05 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $26.99
Real-time Price: $26.94 info
Change: -$0.050 (-0.19%) info
Market Cap: $1.761B info
STOK
Oct 29, 2026, 4:01 PM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $26.36
Real-time Price: $26.94 info
Change: +$0.580 (+2%) info
Market Cap: $1.761B info
STOK
Oct 21, 2026, 4:42 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $25.68
Real-time Price: $26.94 info
Change: +$1.26 (+5%) info
Market Cap: $1.761B info
STOK
Oct 05, 2026, 7:00 AM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $25.62
Real-time Price: $26.94 info
Change: +$1.32 (+5%) info
Market Cap: $1.761B info
STOK
Aug 03, 2026, 5:04 PM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $27.95
Real-time Price: $26.94 info
Change: -$1.01 (-4%) info
Market Cap: $1.761B info